APBA3

Across TCGA pan-cancer cohorts, APBA3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated APBA3 data layer compared with 26 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher APBA3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated APBA3 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

HNSC, LUAD, and UCEC are the cancer types where APBA3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Quartile	III,IV	0.964	0.674	.014	23	view →
LUAD	DFS	Tertile	All	0.911	0.466	.003	17	view →
UCEC	DFS	Median	All	0.936	1.000	.023	14	view →
LSCC	DFS	Quartile	II,III,IV	0.879	1.000	.018	4	view →
CCRCC	OS	Quartile	II,III,IV	0.929	0.566	.009	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

APBA3–HNSC (DFS)

Open the HNSC breakdown →